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Abstract: High-throughput molecular screening is required to investigate the origin and 
diffusion of antimicrobial resistance in pathogen outbreaks. The most frequent cause of human 
infection is Escherichia coli, which is dominated by sequence type 131 (ST131), a set of rapidly 
radiating pandemic clones. The highly infectious clades of ST131 originated firstly by a 
mutation enhancing virulence and adhesion. Secondly, single-nucleotide polymorphisms 
occurred enabling fluoroquinolone-resistance, which is near-fixed in all ST131. Thirdly, broader 
resistance through beta-lactamases has been gained and lost frequently, symptomatic of 
conflicting environmental selective effects. This flexible approach to gene exchange is worrying 
and supports the proposition that ST131 will develop an even wider range of plasmid and 
chromosomal elements promoting antimicrobial resistance. To stymie ST131, deep genome 
sequencing is required to understand the origin, evolution and spread of antimicrobial resistance 
genes. Phylogenetic methods that decipher past events can predict future patterns of virulence 
and transmission based on genetic signatures of adaptation and gene exchange. Both the effect of 
partial antimicrobial exposure and cell dormancy caused by variation in gene expression may 
accelerate the development of resistance. High-throughput sequencing can decode measurable 
evolution of cell populations within patients associated with systems-wide changes in gene 
expression during treatments. A multi-faceted approach can enhance assessment of antimicrobial 
resistance in E. coli ST131 by examining transmission dynamics between hosts to achieve a goal 
of pre-empting resistance before it emerges by optimising antimicrobial treatment protocols. 
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1. The advent of genome-based Escherichia coli monitoring 
 
The rate of infectious disease outbreaks globally increased significantly during 1980-2013 [1,2]. 
Understanding the transmission dynamics of antimicrobial resistance (AMR) during infections 
necessitates deep molecular screening [3,4]. The most informative tools for epidemiological 
investigation of AMR exploit emerging high-throughput technologies [5], of which genome 
sequencing is becoming standard for resolving the origins of outbreaks over timespans ranging from 
centuries to days [6]. Only such tools can trace the transmission of infection outbreaks: other genetic 
profiling methods such as multi-locus sequencing typing (MLST) of housekeeping genes or pulse-field 
gel electrophoresis (PFGE) are not sufficiently discriminatory [7]. 
 
Although PFGE is still used internationally for reconstruction the evolution of bacterial outbreaks, its 
reproducibility between labs can be inconsistent [8] due to variability in genome-wide restriction 
enzyme site frequency. This can be reduced with use of standardised protocols, materials, and 
interpretive criteria. However, its low discriminatory power for ST131 [9] suggests other methods are 
superior [10]. 
 
MLST has moderate power to determine sequence type (ST) given sufficient elapsed time [11] but is 
limited by selecting a small number of genes from the genome [12] (Table 1). The Pasteur MLST 
system genes numbers eight genes: DNA polymerase (dinB), isocitrate dehydrogenase (icdA), p-
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aminobenzoate synthase (pabB), polymerase PolII (polB), proline permease (putP), tryptophan 
synthase subunits A and B (trpA/trpB) and beta-glucuronidase (uidA) 
(www.pasteur.fr/recherche/genopole/PF8/mlst/EColi.html). This differs from the Achtman scheme, 
which uses seven housekeeping genes: adenylate kinase (adk), fumarate hydratase (fumC), DNA 
gyrase subunit B (gyrB), icd, malate dehydrogenase (mdh), adenylosuccinate dehydrogenase (purA), 
ATP/GTP binding motif (recA) [13]. Over shorter timescales, MLST is limited [14]: genome 
sequencing can be considered simply as an extension of MLST that offers an expanded set of genes 
and thus finer resolution, which is critical for fighting rapid clonal expansions. 
 
The comprehensive profiling provided by genome sequencing has enabled the production of new 
antimicrobials, diagnostics and surveillance systems, and is a fundamental shift in practice in 
infection control that enables more accurate pathogen tracing [15]. An example is the 
enteroaggregative ESBL E. coli O104:H4 summer 2011 outbreak that infected thousands and 
killed many in France and Germany [16]. Its source was initially misidentified (but later clarified 
as fenugreek seeds), and the incubation time in patients was eight days, and progression from 
diarrhoea to haemolytic-uremic syndrome a mere five days [17]. This indicates a short timespan 
for the medical application of molecular technologies. The draft genome was sequenced within 
three days and a consensus genome sequence was reconstructed within two further days [18], 
allowing validation of discovered AMR markers within 16 days [19]. In other examples, genome 
sequencing successfully determined the number of origins of ST131 CMT-X-15-positive 
infections in a neonatal unit [20] and in enterohaemorrhagic O157:H7 isolates [21]. Similar 
strategies have worked in clinical settings for other bacterial species like Staphylococcus aureus 
and Clostridium difficile [22]. 
 
Recent methodological advances have dramatically improved the accuracy and cost efficiency of high-
throughput sequencing technologies, primarily in relation to genome sequence contiguity through 
better library preparation or genome assembly. At present, genomes can be amplified from just 20+ pg 
DNA [23] or even single colonies [24], and up to 384 samples can be sequenced simultaneously [25]. 
Sequencing single bacterial cells would not require prior cultivation, and therefore could detect cells 
on environmental surfaces [26], as well as removing biases associated with growing large numbers of 
cells, which favours those best-suited to media or that grow faster. Sequence depth and repetitive 
sequence biases can be reduced by using microwell displacement amplification systems. These have 
produced assemblies of over 90% of an E. coli genome [27]. De novo assembly of E. coli and other 
bacterial genomes as a single unit using long sequence reads is now viable using single-molecule real-
time sequencing [28,29]. This approach can differentiate carbapenemase-producing elements in E. coli 
[30], determine the precise origins of the linked mobile genetic elements (MGEs) like insertion 
sequences (ISs) [31], and also create gapless enterohaemorrhagic O157:H7 EDL933 genome with no 
ambiguous SNPs [32]. Additionally, other strategies like nanopore sequencing have produced high-
resolution E. coli genomes [33].  
 
2. Escherichia coli ST131 is a major global health issue 
 
E. coli is the most frequent cause of acute bacterial infections [4], particularly blood stream infections 
(BSIs) and urinary tract infections (UTIs) [34]. E. coli causing UTIs and BSIs are not genetically 
distinct and can transfer between distinct environments [35]. Uropathogenic E. coli cause 80% of UTIs 
[36] and infect 20% of adult women at least once in their lifetime [37]. Approximately 50% of 
hospital-acquired (HA) and 70-95% of community-acquired (CA) UTIs are caused by E. coli, and 
these are suspected to originate from intestinal colonisers [37,38]. There are multiple potential sources 
of E. coli UTIs and BSIs because it contaminates food [39,40,41] such as fruit [42] and meat [43], and 
infects companion animals [44] like cats [45] and dogs [46].  
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E. coli are the most frequent extended spectrum beta-lactamase (ESBL)-producing bacterial species 
and are common globally: ESBL-producers account for 19-61% of E. coli in Spain [47], 41% in Israel 
[48], 41% in Japan [49], 47% [50] to 56% [51] in the USA, 78% in Canada [52] and 91% in Ireland 
[53]. The most significant threat among ESBL E. coli is sequence type O25b:H4-B2-ST131, a set of 
pandemic clones from phylogroup B2 that is dominant worldwide [54,55,56]. B2 is associated with 
extraintestinal infection, but is also present asymptomatically in humans [57,58]. There is evidence 
that B2 diverged early among E. coli groups and is composed of nine subclasses [59], of which ST131 
is a basal group [60]. O25b ST131 has been detected in many countries, and serotypes O16:H5, O(not 
typeable):H4, and O157 have also been observed in Australia [61], China [62], Denmark [63], Japan 
[64], Spain [47], the USA [65] and the UK [54,66].  
 
Even though it was first reported in 2002 [67], ST131 is not new. Global ST131 isolates taken from 
humans, animals and environmental locations evaluated using PFGE include samples from 1967, 1982, 
1983, 1985, 1986, and 22 from 1990-99 [50]. The earliest other ST131 are from Sweden and Britain 
and date to 1968, with others from the 1970s (7), 1980s (9) and 1990s (16) [68] – as well as one from 
1985 [65].  
 
Bacterial AMR is a major threat to public health [69]: AMR in E. coli is evident worldwide [4] and 
encompasses many compounds [24,70]. AMR in E. coli is becoming more frequent [71] and is driven 
by environmental exposure [72], such as in effluent waste water [73,74] and soil treated with manure 
from antibiotic-treated livestock [75]. In the UK from 1991-2012, antibiotic treatment failure jumped 
by ~12% and was more frequent in certain second-line antimicrobials (such as quinolones and 
cephalosporins) than in first-line ones (penicillins, macrolides, flucloxacillins) [76]. 75% of E. coli 
from 1997-2007 in Irish hospitals displayed AMR to eight or more of 16 antimicrobials [77]. ESBL-
producing E. coli are resistant to cephalosporins and fluoroquinolones, leaving carbapenems as the sole 
last-resort antimicrobial [4]. However, multi-AMR ESBL E. coli with carbapenem-resistance are now 
detected with alarming frequency [78] and in Algeria [79], China [80] and Ireland [81] for ST131.  
 
ST131 represents a universal problem whose evolutionary epidemiology needs deeper study. Little is 
known about how it evolves and spreads on a local scale [82] despite a high infection rate in neonatal 
[20,83,84,85] and childcare facilities [86]. As a fraction of total E. coli infections, ST131 infection 
rates are proportionally higher in long-term care facilities (LTCFs) (76%) than hospitals (49%) and the 
public (15%) [87]. This may be driven by the acquisition of CTX-M (cefotaximase) elements, which 
are beta-lactamases (bla) that hydrolyse beta-lactam rings [88]: UTIs caused by blaCTX-M-positive 
ST131 are now common in LTCFs [89], hospitals [90] and the community [91]. Current hypotheses on 
the sources of E. coli have identified LTCFs as a closed microenvironment in which AMR bacteria 
evolve [92], and subsequently they diffuse into the wider community, spreading AMR alleles [93].  
 
3. The genomic landscape of antimicrobial resistance in E. coli  
 
Commonly E. coli genomes are separated into the largely chromosomal highly-conserved core genome 
and the accessory genomes. Notably, the core genome varies between studies [94] because it is 
composed of genes present in all samples for that analysis [95]. The accessory genome typically has 
much lower sequence conservation and encodes non-essential traits associated with virulence and 
antimicrobial metabolism [96]. It represents a major component of microbial variation and includes 
MGEs like plasmids, transposable elements (TEs), pathogenicity islands, and prophages.  
 
E. coli undergo extensive horizontal gene transfer (HGT) [97]: HGT accounts for ~31% of genome-
wide variation in ST131 [98]. Genes arising by HGT are frequently associated with duplications, 
which can permit new functions among the two gene copies [99]. HGT typically occurs through three 
processes: the primary one is transduction via bacteriophages after cell lysis and invasion via 
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homologous recombination. ST131 acquire AMR through extrachromosomal MGEs from 
bacteriophages [100], or the integration of prophage DNA into chromosomes [101]. Prophage 
elements account for over 35% of E. coli CDS variation [102], and encode genes linked to virulence 
[103], growth during nutrient deficit [104], transcriptional regulation [105], AMR [106] and biofilms 
[107]. During generalised transduction, HGT segment length is a function of phage type. Other options 
for HGT are the transformation of local DNA from dead cells, or conjugation mediated by plasmids, 
TEs, integrons or integrating conjugative elements (ICEs). Homologous recombination between ICEs 
increase their diversity [108]. TEs such as ISs have a high frequency of integration and excision, and 
mediate both AMR gene composition and their expression rates. Although HGT is generally a function 
of sequence homology, but TEs do not need high levels to insert. 
 
More detailed knowledge of AMR gene types and expression rates can help optimise antimicrobial 
treatments [109,110]. A large number of ST131 genomes have been published. The first was NA114 
from an Indian UTI: a 4,936 Kb genome with a GC content of 51.2% and of which 88.4% was coding 
sequence (CDS) [111]. In comparison, genome JJ1886 from a UTI was 5,130 Kb and genetically more 
representative of the super-spreading subgroups within ST131 [112]. Notably, JJ1886 contained a 
chromosomal CTX-M-15 element due to a partial insertion of a Tn3 element into a lambda-like 
prophage locus. Isolate EC958 from the UK was also blaCTX-M-15-positive and provided a 50.7% 
GC 5,110 Kb genome somewhat distinct from NA114 and JJ1886 [113], perhaps due to its earlier 
isolation date. It is important to note that the number of genes, tRNAs and rRNAs in NA114 (4,875; 67; 
3), JJ1886 (5,086; 88; 22) and EC958 (4,982; 89; 7) may differ due to differences in sequence library 
preparation and genome assembly: comparisons must be cognisant that not all genomes are created 
equal. 
 
4. Antimicrobial resistance genetically defines ST131 
 
The most closely related clonal complexes (ST1876 and ST95) provide a genetic definition for ST131 
(Figure 1). ST131 possesses a variety of genes associated with virulence [47,114] and pathogenesis 
[115] (Table 1). A key one is the fimH gene encoding a type 1 fimbrial adhesion protein expressed on 
the cell membrane. ST131 encompasses firstly serotype O16:H5 with a fimH41 allele: this is 
equivalent to Clade A from Petty et al [116]. ST131 secondly includes serotypes O25b:H4, some of 
which possess fimH22 allele, corresponding to Clade B [116]. Genomes from 1967, 1983 (avian 
infection), 1985, 1990 (avian), 1992, 1995 (chicken) and 1997 were all fluoroquinolone-sensitive 
fimH22 (Clade B) ST131 [98]. Genome sequencing and the Pasteur MLST system can distinguish 
O16:H5 from O25b:H4, but not the Achtman MLST scheme. 
 
The remaining ST131 belong to a group named H30 (or Clade C [116]) defined by their acquisition of 
a fimH30 allele: the earliest date of appearance of H30 is at least 1997 [50]. A minority of H30 appear 
to have lost fimH30 for fimH22/35 or rarer fimH variants [118]. Fluoroquinolone-sensitive ST131 was 
common prior to 2000, but is now rare. This is due mutations in two genes encoding DNA gyrase 
subunit A (gyrA) and DNA topoisomerase 4 subunit A (parC). Nested within H30 is H30-R, which 
accounts for 58% of ST131 and is becoming more prevalent [116]. H30-R is nearly always 
fluoroquinolone-resistant – but this can be lost [118]. 
 
A subgroup of H30-R named H30-Rx is a recent radiation dating to at least 2002 and is nearly always 
blaCTX-M-positive [98,116]. Just three genome-wide SNPs distinguish H30-Rx from other H30-R. It 
is the main driver of increasing rates of fluoroquinolone-resistance [120]. BlaCTX-M-15 is the most 
frequent H30-Rx CTX-M element type and originated from Kluyvera in the early 2000s [119], such 
that 49% of E. coli LTCF samples from 2004-2006 were blaCTX-M-15-positive ST131 [121]. Other 
older fluoroquinolone-resistant blaCTX-M-15-positive H30-Rx with published genomes predating 
2006 are EC958 (March 2005) [113], several from 2000-05 isolated in Canada [116], and from 2002 
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again in Canada, but also 2003 in Korea and 2005 in Portugal [98]. Such isolates could be essential for 
determining the origins of H30-Rx. BlaCTX-M-15 is also found less commonly in ST38, ST405 and 
ST648 [120]. 
FIGURE 1. ST131 GENETIC GROUPS AND ACQUISITION OF DRUG-RESISTANCE CHANGES.  
 
 
THIS CLADOGRAM SHOWS ST1876 AND ST95 AS THE MOST CLOSELY RELATED CLONAL COMPLEXES TO 
ST131 (WITH PUBLISHED GENOMES). H41 IS IN SEROTYPE O16:H5 AND IS KNOWN AS CLADE A (H41) 
[116]. H22 IS A SET OF O25B:H4 ST131 CALLED CLADE B [116]. H30 IS A SUBGROUP OF O25B:H4 
ST131 DEFINED BY THEIR ACQUISITION OF THE FIMH30 ALLELE (DARK GREEN) [98]: THIS IS CALLED 
CLADE C. H30-R IS A SUBSET OF H30 THAT ARE NEARLY ALWAYS FLUOROQUINOLONE-RESISTANT 
(EMERALD GREEN), LARGELY DUE TO ALLELES 1AB IN GYRA AND 1AAB IN PARC. WITHIN THIS GROUP, 
H30-RX HAVE BLACTX-M-15 (BRIGHT GREEN) [98] BUT NOT ALWAYS [116]. THIS DIAGRAM DOES NOT 
MEAN THAT H30, H30-R OR H30-RX ARE MONOPHYLETIC [68]. 
 
5. The key antimicrobial resistance elements in ST131 
 
Numerous core genome mutations are implicated in ST131’s AMR [122]. These include regulators of 
drug efflux, repressor of the marRAB (multiple antibiotic resistance) operon (marR), and repressor of 
acrAB (achromobactin outer membrane receptor) genes (acrR), that respond to drugs associated with 
high fitness costs. Others are L42R in ribosomal gene S12 (rpsL105); a transposon mediating 
resistance to tetracycline (Tn10); S80I and E84V in parC to fluoroquinolones; ciprofloxacin and 
nalidixate thanks to changes at gyrA (most frequently S83L and D87N) [123]. Chromosomal ampC-
like cephalosporinases are also common in E. coli [48]. 
 
ST131’s virulence genes are used to categorise it into distinct virotypes [68]. The aerobactin receptor 
(iutA), group 2/3 capsule synthesis (kpsM II/III) and fimH genes are part of a system for defining 
extraintestinal E. coli [124,125]. These are markers for H30-Rx, along with Afa adhesion (afa), Dr-
binding adhesion (dra), virotype A and capsule (K100) genes [68]. ST131 virulence factor genes are 
typically located in pathogenic islands or MGEs and encode toxins, adhesions, lipopolysaccharides, 
polysaccharide capsules, proteases, and invasins (Table 1). Other genes universal in ST131 include 
secreted autotransporter toxin (sat), yersiniabactin receptor (fyuA), uropathogen-specific protein (usp), 
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pathogenicity island marker (malX), adhesion receptor (iha), outer membrane receptor (ompT), 
aerobactin (iucD) and serum resistance associated (traT) [126]. 
 
ST131 has different plasmids from multiple incompatibility groups (Inc) such as IncF, IncI1, IncN and 
IncA/C. IncF are limited to Enterobacteriaceae, are the most frequent plasmids in ST131 [127], and 
have a major role in determining AMR. Typically they are >100kb long and maintained at a low 
number of copies. Three types of IncF plasmids have been found in ST131, not including complex 
fusions: IncFIA, IncFII and IncI1 [127]. These plasmids typically possess multiple AMR, beta-
lactamase, virulence, toxin and antitoxin elements. Conjugation of IncFII plasmids have facilitated the 
pervasive spread of blaCTX-M elements, especially blaCTX-M-15. A majority of isolated ST131 have 
IncFII pEK516 plasmids, which has 103 genes including blaCTX-M-15, blaOXA-1, blaTEM-1, 
chloramphenicol acetyltransferase (catB4), tetracycline efflux pump (tetA) and plasmid stability (stbB) 
for stable plasmid inheritance [128]. In the latter study, plasmid pEK516 also contained 
aminoglycoside acetyltransferases allowing resistance to aminoglycosides, ciprofloxacin (both via 
aac(6’)-Ib-cr) and gentamicin (via aac(3)-II). 
 
Plasmids contain genes encoding various beta-lactamases that are grouped into Ambler classes A 
(blaCTX-M, blaTEM, blaKPC, blaSHV); B (blaVIM, blaNDM, blaIMP); C (blaCMY, ampC-related 
like blaDHA); D (blaOXA). Classes A/C/D use serine for beta-lactam hydrolysis, whereas B are 
metallo-beta-lactamases that use divalent zinc ions [129]. Beyond blaCTX-M in class A, TEM beta-
lactamases are the most frequent ESBL in E. coli more broadly. They are exchanged extensively 
between species: for example, TEM-52C in E. coli is mediated by an IncI1-g plasmid on a Tn3 
transposon [130] and has been found in Salmonella [131]. SHV beta-lactamases are less common in E. 
coli, but are abundant in K. pneumoniae, from which ST131 has acquired other beta-lactamases [132].  
 
Class A KPC-2 (K. pneumoniae carbapenemase) is the most common carbapenemase type [120]. This 
can impair cephalosporins, monobactams and penicillins, as well as carbapenems, and has spread to 
China [80], France [133], Ireland [78,81] and the USA [134]. Other carbapenemases include class B 
metallo-beta-lactamases like Verona integron-encoded metallo-beta-lactamase (VIM), which has been 
found in Italy [135], and blaIMP-8, which has been detected in Taiwan [136].  
 
Class B NDM-1 (New Delhi metallo-beta-lactamase)-positive ST131 has been found in India [137] 
where it may have originated in E. coli by in vivo conjugation with K. pneumoniae in 2009 or earlier 
[132]. BlaNDM-1-positive ST131 is now common in northern India (6% in Varanasi [138]), southern 
India (7% in Mumbai [139]) and northern Pakistan (15% [140]). BlaNDM-1 has been found on fast-
spreading IncFII plasmids as well, along with Class D carbapenemase blaOXA-1 (oxacillinases) 
together with aminoglycoside resistance genes [141]. The rapid spread of blaNDM-1 in many species 
provides an example of how easily certain AMR genes can be spread. 
 
Lastly, class C includes plasmid-mediated ampC beta-lactamases blaDHA-1 [49], which was first 
found in Salmonella enterica [142], and blaCMY-4 (active on cephaycins) [48] and blaCMY-2 
[49,143] – the latter is a cephamycinase originally transferred from Citrobacter species. Some ampC 
genes are chromosomal, but possess a much lower expression rate than the more common plasmid-
mediated ampC genes [48]. 
 
6. How did ST131 adapt to be so successful?  
 
Bacterial infectious disease is driven in part by rapid mutation rates (~10
-5
 per genome per generation 
in E. coli) [144], short generation times [145], and non-lethal antimicrobial doses due to non-adherence 
[146]. Remarkably, AMR may have no fitness cost and may even increase fitness in E. coli [147,148]. 
ST131 is highly resistant without any fitness cost [127], even more so in CA compared to HA ST131 
7 
 
isolates [149]. As outlined, the three key changes define H30-Rx ST131: the acquisition of fimH30, 
fluoroquinolone-resistance switches and beta-lactamase gains. In contrast to the single acquisitions of 
fimH30 and fluoroquinolone-resistance, the type of beta-lactamase varies, and they are lost and 
recovered frequently. Consequently, antimicrobial treatments have inadvertently created the H30-Rx 
superbug, and associated fitness costs may be linked with beta-lactamases, but less so for fimH30, 1AB 
in gyrA and 1aAB in parC. As acknowledged above, there are rare cases of fimH30 loss and gyrA/parC 
mutation within H30-Rx. 
 
(i) Extensive horizontal gene transfer 
ST131 is common in UTIs and BSIs, but not at other anatomical locations [150]. In spite of pervasive 
HGT, DNA exchange with other bacterial species is rare, affecting just ~0.4% of the core genome 
conserved across the E. coli genus [151]. UTI-causing ESBL-positive ST131 acquire resistance 
through HGT with other ST131 colonising the same individual, but rarely from other E. coli 
phylogroups [54]. Indeed, ST131 is frequent in poultry [152] but retains a distinct set of blaCTX-M 
and blaTEM-52 elements despite high overall genetic similarity [153]. Naively, this suggests previous 
HGT with Kluyvera [119] and K. pneumoniae [132] is rare. However, recent examples of K. 
pneumonia derived plasmids contributing blaCTX-M-27 genes to ST131 [154] is consistent with a 
proposal of alarming potential genetic flexibility in ST131.  
 
(ii) Maintenance of a broad resistome  
ST131 regulates the activity of its resistome: its entire complement of AMR genes. There is evidence 
of functional robustness and redundancy in the resistance mechanisms of E. coli’s “proto-resistome” 
comprising penicillin-binding proteins, cell wall modifying enzymes and cell division genes [155]. A 
sequencing approach could assess this in a comprehensive manner. Expression of 61 genes is 
associated with small increases in tolerance to 86 antimicrobial-related compounds [156]. Many 
potential AMR genes remain unknown in E. coli [157], even though their activities vary even within 
putatively clonal cell populations [158] and the mechanism of action of many antimicrobials remains 
unclear [159].  
 
(iii) Regulatory fine-tuning of gene expression 
Regulatory sequences alter AMR through gene expression levels [160] including bursting [161] and 
transitions between pathogenic and non-pathogenic states [126]. Promoters evolved to alter gene 
expression rates in response to rapidly changing environmental conditions [162], which can affect 
AMR phenotypes by up to 10
6
-fold [163]. Promoter gene expression regulation is higher at non-
essential genes with lower sequence conservation, and their activity rates are more variable than those 
of essential genes [164]. During multi-drug exposure, 30% of E. coli expression variation is attributed 
to promoter mutations [165] – for example, a mutation T32A at a beta-lactamase ampC gene promoter 
elevates expression rates genome-wide [166]. 
 
(iv) Cross-antimicrobial resistance and compensatory mutations 
Synergy and antagonism between different antimicrobials is pervasive [167], even to the point that 
simultaneous synergy and antagonism is possible (a Harvey Effect). Some compensatory mutations are 
specific to individual antimicrobials but others promote cross-AMR simultaneously [168]. Feedback-
based cross-AMR in response to combination treatments is a function of the number of unlinked 
(positive) gene regulatory networks [169]. AMR is reduced by negative epistasis during cyclical 
treatment, which decreases resistance to both drugs more effectively than to single drugs – nearly as 
well as dual drug therapies [170]. Certain compensatory mutations alter AMR without being clearly 
associated with the phenotype – for instance, blaCTX-M-linked carbapenem-resistance requires water 
channel (porin) gene loss to mitigate fitness costs [171]. Additionally, structural rearrangements at ISs 
are associated with rapid increases in fitness during long-term E. coli evolution [172]. 
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(v) Resistance through cell growth arrest  
Antimicrobials limit E. coli growth [173], which is controlled by gene expression [174]. Growth 
depends on environmental conditions and is controlled by the concentration of transcription-associated 
proteins [175]. Even without a specific stress, cells spontaneously enter and exit a quiescent non-
growth state during both log and stationary growth phases [176]. Lowered expression is more strongly 
associated with non-essential genes like toxins [164]. There are 22 toxin-antitoxin systems in E. coli 
K12 that can be recruited during environmental stress to regulate growth, affecting biofilm formation 
[177]. For example, in the hipBA toxin-antitoxin system, antitoxin HipB represses serine-threonine-
protein kinase HipA but has a short half-life. When HipB levels fall, HipA phosphorylates a glutamyl 
tRNA synthetase to mimick starvation [178], reducing translation and slowing growth, resulting in a 
non-growing phenotype [179]. 
 
7. Stopping ST131:  
 
(i) Evolutionary phylogenomics and fitness measurement 
Pathogens resist antimicrobials by evolving: consequently, analysis of evolution is needed [180] which 
should operate on a genome-wide basis for outbreaks like ST131 to more finely resolve of 
evolutionary patterns at all potential AMR factors [181]. Genome-based evolutionary analysis and 
real-time diagnostic evaluation is now as cheap and time-effective as conventional approaches [182] 
and informative bioinformatics strategies now underpin improvements in clinical microbiology [183].  
 
Variation arising by recombination between strains can be deduced from the genome-wide DNA 
mutation density distribution [181]: signatures of HGT have much higher polymorphism rates, 
reflecting the mutational time spent in a different species [184]. For H30-Rx, this includes MGEs, 
integrated phage DNA and capsule-related genes [185]. Comparing the most likely genealogy at a 
given panel of SNPs (haplotype) to the mean signal across the genome can identify ancestral and 
recent recombination between and within subpopulations [186] and determine the phylogeographic 
origin of specific recombination events in a coalescent framework [187]. Phylogenetic and 
genealogical histories at regions arising through HGT deviate substantially from the mean genome-
wide phylogenetic signal [188,189].  
 
New beneficial variants increase in frequency faster than average [190] and retain a more recent time 
of origin [191]. Phylogenetic branching topology can measure relative fitness assuming a persistent 
source of antimicrobial pressure causing mutations with small fitness effects [192]. The latter is valid 
for E. coli because many genes regulate AMR and virulence [156,193]. No variation in relative fitness 
would mean low variability in the rates of coalescence of descendent nodes compared with ancestral 
ones. In contrast, a high difference in relative fitness would mean highly fit ancestors will produce 
many more descendent nodes. This would appear as a radiating population: such as H30 within ST131, 
H30-R within H30, H30-Rx with H30-R; what will follow H30-Rx? 
 
(ii) Modelling historical and future epidemiology 
Systematic monitoring of infection and transmission in human populations can be used to infer sources 
of ST131, including from potential reservoirs like livestock and intestinal colonisers [61]. Current 
hypotheses pinpoint the Indian subcontinent as a possible original reservoir for ST131. During the 
discovery of ST131 in 2008, there was a high rate of recent travel to this region in those with H30-Rx 
ST131 infection in New Zealand [194] and Canada [195,196]. Whether this was caused by both a 
single H30-Rx clone and through plasmid-mediated HGT is unclear [197] due to the limited sampling 
of the Indian subcontinent prior to 2002. With extensive geographic sampling including samples 
particular during the acquisition of fimH30 in the 1990s and fluoroquinolone-resistance sometime 
before 2002, phylogenomic reconstruction would address this puzzle. 
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Genome sequencing can help address the rise of AMR [38] by predicting future resistance. The most 
likely future dominant subtype of a pathogen is typically the most fit one [198]: this can be applied to 
ST131 based on de novo and known mutations at key AMR determinants using frameworks developed 
for viruses [199]. The relative rate of allele frequency change reflects its association with antimicrobial 
selection pressure [200], and can be measured from time-series genome data [201] to distinguish this 
effect from drift [202]. Such sampling over extended periods allows the identification of genes 
implicated in adaptation based on the mutation’s age, functional effects, and ancestral phylogenetic 
position [203].  
 
Phylodynamic models determine future evolutionary and epidemiological patterns based on 
phylogenetic tree structure [204]. Such schemes have revealed missed events during transmission of 
tuberculosis [205], pin-pointed an asymptomatic spreader of methicillin-resistant S. aureus between 
babies [206], assessed the potential for multiple simultaneous outbreaks to originate from the same 
common ancestor [207], and examined evidence for multiple origins of infection [208]. Although such 
methods have not yet been applied to E. coli, they can enhance our understanding of the inter-host 
spread of AMR.  
 
(iii) Assessing cell growth arrest 
Stochastic phenotype switching is common to all domains of life, is accentuated by antimicrobial stress, 
and in bacteria is observed as changes in gene expression. This growth-dormancy bistability is an 
evolutionary bet-hedging strategy that results in a mix of cells with varying gene expression rates [209]. 
It arises due to gene regulatory network structure, leading to rare but occasional switches from the 
growing wild-type (WT) state to a non-growing dormant one. Cell-cell interactions may affect 
variation in gene expression rates [210], allowing this randomness to adaptively drive regulatory 
changes. 
 
Cell dormancy causes large shifts in metabolic gene expression [211,212]. This contrasts with 
ribosomal gene expression that has buffering mechanisms [174,213] and so scales linearly with cell 
growth [214]. E. coli alter their carbon metabolism rapidly [215] by co-regulating enzymes to cope 
with rapidly changing environmental conditions [216]. However, metabolic flux is regulated 
extensively [217,218] so differing concentrations can produce the same net metabolic effects [219,220] 
or affect other pathway components [221]. E. coli optimise gene expression by moderating ribosome 
production [222]: this means shifts in metabolic gene expression can be compared to those for 
ribosomal RNA, which should match the antimicrobial toxicity and bacterial AMR level. AMR-driven 
changes in gene expression vary non-monotonically with dose and are a function of the complexity of 
the mechanism: antimicrobials inactivating targets may elicit higher target expression, whereas drugs 
causing gain-of-function changes may cause mutation [110]. This means the relative rates of metabolic 
and ribosomal gene activity provide sufficient information to deduce AMR levels and types. 
 
(iv) Avoiding partial treatments and cell population heterogeneity 
Suboptimal treatment regimens [34], poor compliance [223] and drug pharmacokinetics [224] lead to 
spatial structure in antimicrobial concentrations. This is frequent in human and animals both at an 
individual level [225] and in groups of treated and untreated patients [226]. At low antimicrobial doses 
(such as a minimal selective concentration [227]), WT and resistant cells grow equally well, whereas 
only resistant cells would survive when exposed to dose greater than the minimal inhibitory 
concentration (MIC). Partial treatment regimens accelerate AMR for mechanisms requiring numerous 
mutational steps with small fitness costs by offering a sub-MIC sanctuary where resistant cells can 
evolve further despite transiently lowered fitness [226]. However, partial regimens can slow AMR if it 
requires few mutational steps or substantial temporary falls in fitness [229]. In addition, the mutational 
time required for resistance emergence may be a function of cell density [230]. 
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Spatial or temporal variation in treatment application allows WT cells more time to accrue new 
mutations, causing faster AMR evolution [228]. These genetically resistant cells are known as type 1 
persisters to differentiate them from type 2 persisters that are resistant due to gene expression control 
causing non-growth [231]. Although E. coli type 2 persister gene activity depends on adjacent cells 
[165], they revert to growth after dormancy ends, and attain exponential growth rates once resistant 
mutations occur when all WT cells have died [232]. These type 2 persisters may require a genetic 
predisposition [231] and initially comprise just 0.001% of cells [233]. 
 
(v) Dissecting measurably evolving infections 
A single ST131 infection may become a genetically diverse cell community descended from a recent 
common ancestor driven by antimicrobial selective pressure. Multiple populations could exist: for 
example S. aureus measurably evolves (30 SNPs and 4 indels in 16 months) to magnify virulence 
[234]. Furthermore, distinct Burkholderia dolosa lineages co-exist within individual cystic fibrosis 
patients for years and have undergone extensive clonal interference during exposure to antimicrobials 
[235]. Soft selective sweeps during host adaptation of Pseudomonas aeruginosa are prevalent, 
indicating different loss-of-function mutations may target the same gene within a heterogeneous cell 
community [236]. 
 
Consequently, deep genome sequencing is required to grapple with mutations in a cell population 
[237]. Such population mixes could be described using birth-death [181], logistic growth [238] and 
two-level population models within a single infection [239] or a structured environment [240] to 
optimise antibiotic treatment protocols [241]. However, there are caveats: high-dose antimicrobial 
treatment may give rise to a single dominant variant within the host [110], rare variants may become 
more advantageous at differing rates as the host microenvironment changes [190], and mutants may be 
pre-existing rather than de novo [123]. 
 
Conclusion: Future avenues for ST131 infection genomics 
 
Genome sequencing can predict virulence, toxicity and AMR phenotypes in E. coli ST131 [242]. It is a 
pivotal tool for infection control because it facilitates the decoding of molecular mechanisms of 
treatment resistance [243] and can dissect clonal outbreaks of monomorphic bacteria [244]. It can 
decipher transmission routes and inter-host contact [181], and evaluate genetic diversity within hosts 
over time [245]. This evolutionary approach should become the basis for analysing E. coli ST131 
outbreaks. A final point is that there are several other possibilities for genome-based AMR control not 
discussed here: E. coli post-transcriptional processing disturbs expected correlations between mRNA 
and protein levels [246] – this includes AMR-driven regulatory changes by small RNAs [247]. 
Additionally, epigenetic heterogeneity within E. coli cell populations screened using long-read 
sequencing methylation data [248] is associated with extensive regulatory control of phenotypes [249]. 
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Table 1. Genes associated with virulence or ST131 typing. Genes encoding virulence factors (adhesion, 
capsules, siderophores, antimicrobial resistance (AMR), toxins) and used to define Extraintestinal E. 
coli, H30-Rx ST131 and the Pasteur/Achtman MLST schemes are highlighted.  
 
Gene Name  Gene product Role in virulence Typing use 
H7 fliC 
 
Flagellin variant Multiple 
 
iss 
 
Increased serum survival Multiple 
 
malX 
 
Pathogenicity island marker Multiple 
 
ompT 
 
Outer membrane protease T Multiple 
 
traT 
 
Serum resistance-associated Multiple 
 
usp 
 
Uropathogenic-specific protein Multiple 
 
K1/K2/K5 
 
Group 2 capsule variants Capsule-related 
 
kpsM II 
 
kpsM II group 2 capsule Capsule-related Extraintestinal E. coli definition 
kpsMT III 
 
Group 3 capsule Capsule-related Extraintestinal E. coli definition 
K100 
 
Group 2 capsule variants Capsule-related H30-Rx definition 
afa 
 
Afa adhesin Adhesion H30-Rx definition 
draBC 
 
Dr-binding adhesin Adhesion H30-Rx definition 
fimH 
 
Type 1 fimbriae Adhesion Extraintestinal E. coli definition 
F10 papA 
 
P fimbriae subunit variant Adhesion 
 
focG 
 
F1C fimbriae adhesin Adhesion 
 
hra 
 
Heat-resistant agglutinin Adhesion 
 
iha 
 
Adhesion siderophore Adhesion 
 
papC/papE/papF/papG 
 
P fimbriae operon Adhesion 
 
sfa/foc 
 
F1C fimbriae or S Adhesion 
 
tsh 
 
Temperature sensitive hemagglutinin Adhesion 
 
iutA 
 
Aerobactin receptor Siderophore Extraintestinal E. coli definition 
fyuA 
 
Yersiniabactin receptor Siderophore 
 
ireA 
 
Siderophore receptor Siderophore 
 
iroN 
 
Salmochelin receptor Siderophore 
 
stbB (pEK516 plasmid) 
 
Plasmid stability plasmid stability 
 
catB4 (pEK516 plasmid) 
 
Chloramphenicol acetyltransferase AMR 
(chloramphenicol) 
 
tetA (pEK516 plasmid) 
 
Tetracycline efflux pump AMR (tetracycline) 
 
aac (pEK516 plasmid) 
 
Aminoglycoside acetyltransferases AMR (multiple) 
 
mphA 
 
Macrolide 2'-phosphotransferase I AMR (macrolide) 
 
acrR 
 
Repressor of acrAB genes AMR (multiple) 
 
marR 
 
Repressor of the marRAB operon AMR (multiple) 
 
rpsL105 
 
Ribosomal gene S12 AMR (multiple) 
 
aadA5 
 
Aminoglycoside 3'-adenyltransferase AMR (streptomycin) 
 
sulI 
 
Dihydropteroate synthase AMR (sulfonamide) 
 
Tn10 
 
Transposon - tetracycline resistance AMR (tetracycline) 
 
dfrA7 
 
Dihydrofolate reductase type VII AMR (trimethoprim) 
 
gyrA 
 
DNA gyrase subunit A AMR (fluoroquinolone) 
 
parC 
 
DNA topoisomerase 4 subunit A AMR (fluoroquinolone) 
 
astA 
 
Arginine succinyltransferase Toxin 
 
cnf1 
 
Cytotoxic necrotizing factor Toxin 
 
hlyD 
 
Alpha-Hemolysin Toxin 
 
pic 
 
Serine protease Toxin 
 
sat 
 
Secreted autotransporter toxin Toxin 
 
vat 
 
Vacuolating toxin Toxin 
 
dinB 
 
DNA polymerase 
 
Pasteur MLST system 
pdbB 
 
P-aminobenzoate synthase 
 
Pasteur MLST system 
polB 
 
Polymerase PolII 
 
Pasteur MLST system 
putP 
 
Proline permease 
 
Pasteur MLST system 
trpA/trpB 
 
Tryptophan synthase subunits A, B 
 
Pasteur MLST system 
uidA 
 
Beta-glucuronidase 
 
Pasteur MLST system 
icd/icdA 
 
Isocitrate dehydrogenase 
 
Pasteur/Achtman MLST system 
adk 
 
Adenylate kinase 
 
Achtman MLST system 
fumC 
 
Fumarate hydratase 
 
Achtman MLST system 
gyrB 
 
DNA gyrase subunit B 
 
Achtman MLST system 
mdh 
 
Malate dehydrogenase 
 
Achtman MLST system 
purA 
 
Adenylosuccinate dehydrogenase 
 
Achtman MLST system 
recA 
 
ATP/GTP binding motif 
 
Achtman MLST system 
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